Indolent mantle cell lymphoma.
Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term "indolent MCL". Unlike the recognized histologic variants, the definition of indolent mantle cell lymphoma is unclear, and patients with indolent MCL are often identified only after having undergone prolonged periods of observation. In this review, we will discuss clinical and biologic features and provide a framework for the approach in identifying patients with indolent MCL.
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic , Cleveland, OH , USA.
Eric D
ED
Hsi
Peter
P
Martin
D018450:Disease Progression; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis